Tortugas Neuroscience Emerges from Stealth with $106M to Advance CNS Drug Pipeline Licensed from Eisai and Hansoh
核心洞察
Tortugas Neuroscience (搜索) launched with $106 million in funding led by Cure Ventures (搜索), with former Sage Therapeutics CEO Jeff Jonas at the helm.
The Framingham-based biotech acquired four experimental CNS medicines already in clinical testing from Japanese drugmaker Eisai and Shanghai-based Jiangsu Hansoh Pharmaceutical Group (搜索).
The company's pipeline targets central nervous system disorders (搜索) including schizophrenia (搜索), tinnitus (搜索), and focal epilepsy (搜索) using small molecules with derisked mechanisms of action.
Tortugas Neuroscience (搜索) has emerged from stealth mode with $106 million in funding to advance a pipeline of central nervous system therapeutics licensed from established pharmaceutical companies. The Framingham, Massachusetts-based startup announced its launch on Tuesday with former Sage Therapeutics CEO Jeff Jonas leading the company as chief executive officer.
The financing includes both seed and Series A rounds, with Cure Ventures (搜索) leading the seed investment and participating alongside Column Group (搜索) and AN Venture Partners (搜索) in the Series A. Jonas, who spent a decade building Sage Therapeutics into a publicly traded company with a marketed medicine before stepping down in 2023, now serves as a partner with Cure Ventures.
Licensed Pipeline Targets Multiple CNS Disorders
Tortugas begins operations with four experimental medicines already in clinical testing, all licensed from Japanese drugmaker Eisai and Shanghai-based Jiangsu Hansoh Pharmaceutical Group (搜索). The pipeline consists of small molecules targeting various central nervous system disorders (搜索) including schizophrenia (搜索), tinnitus (搜索), and focal epilepsy (搜索).
According to the company, these medicines feature "derisked mechanisms of action," providing what Jonas described as "a stable clinical foundation" for the startup. The licensed drugs offer "a rare combination of validated mechanisms and a long patent life," Jonas noted in a statement to BioPharma Dive.
Strategic Approach to Biotech Development
The company's model reflects evolving strategies in biotech formation, particularly the increasing trend of venture firms partnering with Chinese pharmaceutical companies to access promising drug candidates. While many such partnerships have focused on oncology, immunology, or metabolic diseases, Tortugas distinguishes itself through its concentration on neurological disorders.
"The process of building a biotech today requires a different blueprint than it did fifteen years ago," Jonas explained, emphasizing how the licensed assets provide an opportunity to quickly build value compared to traditional de novo drug discovery approaches.
Development Plans and Funding Allocation
The $106 million in funding will primarily support the completion of Phase 2 studies for two of the four licensed programs. The company plans to eventually develop additional drugs in-house, according to Jonas, though specific timelines for internal discovery efforts were not disclosed.
The venture capital backing represents confidence in both the neurological disorder space and the strategy of building companies around existing clinical-stage assets rather than starting from early discovery. Tortugas's focus on CNS disorders addresses a therapeutic area with significant unmet medical needs and complex development challenges that have historically deterred many biotechnology companies.